Show trial locations

      A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

      • Cancer
      • Multiple Myeloma
      • Non Hodgkin Lymphoma (NHL)
      • Mature B-Cell Lymphoma
      Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
      Trial Status:


      This trial runs in
      • South Korea
      • United States
      Trial Identifier:

      NCT04045028 GO41036

          Show trial locations

          The source of the below information is public registry websites such as,,, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to and/or and/or

          The below information is taken directly from public registry websites such as,,, etc., and has not been edited.

          Results Disclaimer

          Trial Summary

          This is a Phase I open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab administered as a single agent or in combination with atezolizumab and/or daratumumab or rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R non-Hodgkin lymphoma (NHL).

          Genentech, Inc. Sponsor
          Phase 1 Phase
          NCT04045028, GO41036 Trial Identifier
          Tiragolumab, Daratumumab/rHuPH20, Rituximab, Atezolizumab Treatments
          Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Condition
          Official Title

          A Phase Ia/Ib Open-Label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma, and as a Single Agent and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

          Eligibility Criteria

          All Gender
          ≥18 Years Age
          No Healthy Volunteers
          Inclusion Criteria

          General Inclusion Criteria (All Participants):

          • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
          • Life expectancy of >/= 12 weeks

          Inclusion Criteria Specific to Arms A, C and E (R/R MM):

          • Arm A only: Must have R/R MM for which no established therapy for MM is appropriate and available or be intolerant to those established therapies
          • Arms C and E only: Participants with R/R MM who have received at least 3 prior lines of therapy.
          • Measurable disease defined by laboratory test results.

          Inclusion Criteria Specific to Arms B and D (R/R NHL):

          • Participants with histologically confirmed B-cell NHL who have relapsed or failed to respond to at least two prior systemic treatment regimens and for which no suitable therapy of curative intent or higher priority exists.
          • Must have at least one bi-dimensionally measurable lesion.
          Exclusion Criteria

          General Exclusion Criteria (All Participants):

          • Any anti-cancer therapy, whether investigational or approved, including chemotherapy, monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, hormonal therapy, and/or radiotherapy, within 4 weeks or 5 half-lives of the drug, whichever is shorter, prior to initiation of study treatment
          • Prior treatment with any anti-TIGIT agent
          • Prior treatment with chimeric antigen receptor-T (CAR-T) therapy within 12 weeks before first study drug administration
          • Autologous Stem-Cell Transplantation (ASCT) within 100 days prior to first study drug administration
          • Active or history of autoimmune disease or immune deficiency
          • Known active bacterial, viral (including SARS-CoV-2), fungal, mycobacterial, parasitic, or other infection at study enrollment, or any major episode of infection within 4 weeks prior to first study drug administration

          Exclusion Criteria Specific to Arms A, C and E (R/R MM):

          • Primary or secondary plasma cell leukemia
          • Current or history of CNS involvement by MM

          Exclusion Criteria Specific to Arms B and D (R/R NHL):

          • Uncontrolled hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
          • Current or history of CNS lymphoma
          • Current eligibility for ASCT

          Other protocol defined inclusion/exclusion criteria could apply

          Clinical Research Explained

          Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

          Find out now